A South Korean research team has demonstrated the potential for treating Alzheimer’s disease using non-invasive sound and light stimulation, officially registering a patent for the technology.
Alzheimer’s disease, the most prevalent degenerative brain disorder causing dementia, is characterized by the gradual decline of memory and cognitive function. A primary driver of the disease is the accumulation of amyloid beta, a toxic protein that damages nerve cells in the brain.
Currently, treatment relies heavily on pharmaceuticals. These include antibody therapies designed to remove amyloid beta and symptomatic drugs aimed at slowing cognitive decline. However, a recent study by Italy’s IRCCS institute suggests there is still insufficient evidence that amyloid beta-targeting drugs provide clinically meaningful benefits. Furthermore, these medications carry risks of serious side effects, such as brain swelling or hemorrhage—a significant concern for patients requiring long-term care.
Seeking a safer alternative, a research team led by Professor Son Jong-hee of the Department of Neurology at Hallym University Chuncheon Sacred Heart Hospital found that specific sensory stimulation can improve brain function. The team focused on 40 Hz gamma waves, a type of high-frequency brainwave.
The Power of 40 Hz: Enhancing Memory and Cognitive Function
Gamma waves typically occur during moments of intense concentration or creativity, as they increase synchronization among brain cells to maximize information processing. Specifically, 40 Hz gamma waves are closely linked to memory and cognition, making them a prime target for Alzheimer’s research.
The researchers hypothesized that external stimulation at this frequency could improve brain function without the need for drugs. To test this, they exposed laboratory mice with Alzheimer’s-related genes to 40 Hz sound and light for two hours daily over a 14-day period in a noise-controlled environment.
The results were significant. In spatial memory evaluations, the stimulation group achieved a 71.46% accuracy rate, far outperforming the 43.17% rate of the untreated control group.
Physical Brain Recovery and Reduced Toxic Proteins
The stimulation also led to measurable physical improvements in the brain. In the treatment group, amyloid beta levels in the hippocampus—the brain's memory center—dropped to approximately one-third of the levels found in the control group. Simultaneously, concentrations of acetylcholine, a neurotransmitter vital for memory formation, rose to statistically significant levels.
The research indicates that 40 Hz stimulation shifts the balance of proteins regulating brain cell survival toward a protective state, alleviating cellular damage and addressing the underlying pathology of dementia.
"We have scientifically confirmed that 40 Hz gamma-frequency stimulation activates the neural system and produces therapeutic effects for Alzheimer's," said Professor Son Jong-hee. "This technology will be used to develop systems that allow patients to manage dementia in their daily lives without the risk of side effects."
Having completed the patent registration last month, the team plans to continue developing digital therapeutics and home-use medical devices based on these findings.
